Welcome to the CDC Seasonal Flu website.
Skip directly to the search box, site navigation, or .

  • Contact Us
  • 800–CDC–INFO
  • (800-232-4636)
  • 888–232–6348 (TTY)
  • cdcinfo@cdc.gov

Rapid Diagnostic Testing for Influenza

Information for Clinical Laboratory Directors

On this page:

Rapid Diagnostic Tests for Influenza

The availability and use of commercial influenza rapid diagnostic tests by laboratories and clinics have substantially increased in recent years.

Accuracy Depends Upon Prevalence

The positive and negative predictive values vary considerably depending upon the prevalence of influenza in the community.

Clinical Considerations of Testing When Influenza Prevalence is Low

When disease prevalence is relatively low, the positive predictive value (PPV) is low and false-positive test results are more likely. By contrast, when disease prevalence is low, the negative predictive value (NPV) is high, and negative results are more likely to be true.

If Flu Prevalence is… And Specificity is… Then PPV is… False Pos. rate is…
VERY LOW (2.5%) POOR (80%) V. POOR (6-12%) V. HIGH (88-94%)
VERY LOW (2.5%) GOOD (98%) POOR (39-56%) HIGH (44-61%)
MODERATE (20%) POOR (80%) POOR (38-56%) HIGH (44-62%)
MODERATE (20%) GOOD (98%) GOOD (86-93%) LOW (7-14%)

The interpretation of positive results should take into account the clinical characteristics of the case. If an important clinical decision is affected by the test result, the rapid test result should be confirmed by another test, such as viral culture or polymerase chain reaction (PCR).

Clinical Considerations of Testing When Influenza Prevalence Is High

When disease prevalence is relatively high, the NPV is low and false-negative test results are more likely. When disease prevalence is high, the PPV is high and positive results are more likely to be true.

If Flu Prevalence is… And Sensitivity is… Then NPV is… False Neg. rate is…
MODERATE (20%) POOR (50%) MODERATE (86-89%) MODERATE (11-14%)
MODERATE (20%) HIGH (90%) V. GOOD (97-99%) V. LOW (2-3%)
HIGH (40%) POOR (50%) MODERATE (70-75%) MODERATE (25-30%)
HIGH (40%) HIGH (90%) V. GOOD  (93-94%) LOW (6-7%)

The interpretation of negative results should take into account the clinical characteristics of the patient. If an important clinical decision is affected by the test result, then the rapid test result should be confirmed by another test, such as viral culture or PCR.

Selecting Tests

Many factors should be considered when selecting a test, including the following:  

Information about these characteristics can be found in product inserts and scientific articles, and by contacting the manufacturer.

Changes in Recommended Procedures Can Affect Test Results

Modification by the user can affect test performances and increase false-positive and/or false-negative rates. Such modifications include

When Is Use of Rapid Diagnostic Tests Beneficial?

Influenza Diagnostic Table

Procedure Influenza Types Detected Acceptable Specimens Time for Results Rapid result available
Viral culture A and B

NP swab2, throat swab, nasal wash, bronchial wash, nasal aspirate, sputum

3-10
days 3
No

Immunofluorescence DFA Antibody Staining

A and B

NP swab2, nasal wash, bronchial wash, nasal aspirate, sputum

2-4 hours No
RT-PCR5 A and B

NP swab2, throat swab, nasal wash, bronchial wash, nasal aspirate, sputum

2-4 hours No
Serology A and B

paired acute and convalescent serum samples6

2 weeks or more No

Enzyme Immuno Assay
(EIA)

A and B

NP swab2 , throat swab, nasal wash, bronchial wash

2 hours No
Rapid Diagnostic Tests

Directigen Flu A7
(Becton-Dickinson)

A NP wash and aspirate less than 30 minutes Yes

Directigen Flu A+B7,9
(Becton-Dickinson)

A and B

NP swab2,aspirate, wash; lower nasal swab; throat swab; bronchioalveolar lavage

less than 30 minutes Yes

Directigen EZ Flu A+B7,9
(Becton-Dickinson)

A and B

NP swab2, aspirate, wash; lower nasal swab; throat swab; bronchioalveolar lavage

less than 30 minutes Yes

BinaxNOW Influenza A&B8,9
(Inverness)

A and B Nasal wash/aspirate, NP swab2 less than 30 minutes Yes

OSOM® Influenza A&B9
(Genzyme)

A and B Nasal swab less than 30 minutes Yes

QuickVue Influenza Test4,8
(Quidel)

A and B

NP swab2, nasal wash,
nasal aspirate

less than 30 minutes Yes

QuickVue Influenza A+B Test8,9
(Quidel)

A and B

NP swab2, nasal wash,
nasal aspirate 

less than 30 minutes Yes

SAS FluAlert7,9
(SA Scientific)

A and B Nasal wash/aspirate less than 30 minutes Yes

TRU FLU7,9
(Meridian Bioscience)

A and B

Nasal wash/swab, NP aspirate/swab

less than 30 minutes Yes

XPECT Flu A&B7,9
(Remel)

A and B Nasal wash, NP swab2, throat swab less than 30 minutes Yes
  1. List may not include all test kits approved by the U.S. Food and Drug Administration
  2. NP = nasopharyngeal
  3. Shell vial culture, if available, may reduce time for results to 2 days
  4. Does not distinguish between influenza A and B virus infections
  5. RT-PCR = reverse transcriptase polymerase chain reaction
  6. A fourfold or greater rise in antibody titer from the acute- (collected within the 1st week of illness) to the convalescent-phase (collected 2-4 weeks after the acute sample) sample is indicative of recent infection.
  7. Moderately complex test – requires specific laboratory certification.
  8. CLIA-waived test. Can be used in any office setting. Requires a certificate of waiver or higher laboratory certification
  9. Distinguishes between influenza A and B virus infections

Disclaimer: Use of trade names or commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the Department of Health and Human Services.

Additional Information

CDC logo
USA.gov: The U.S. Government's Official Web Portal Department of Health and Human Services